A new medicine for progressive pulmonary fibrosis
Treatments studied
Part of Lungs & breathing clinical trials.
This study tests an experimental medicine called HSK44459 to see if it can slow down progressive pulmonary fibrosis (PPF), a condition that causes lung scarring and breathing difficulty. The goal is to learn if the medicine can help people keep more of their lung function compared to a placebo.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been told you have progressive pulmonary fibrosis (PPF), but not idiopathic pulmonary fibrosis (IPF).
- You have not taken nintedanib or pirfenidone for at least 8 weeks before the study, or you have been on a steady dose of one of these for at least 12 weeks.
- Your recent lung function test (FVC) shows at least 45% of what is expected for your age.
- Your carbon monoxide diffusing test (DLCO) is between 25% and 90% of what is expected.
- You do not have significant airway blockage (FEV1/FVC below 0.7) or a recent flare-up of your lung disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests whether inhaled treprostinil can slow progression of lung fibrosis (scarring) that keeps getting worse despite standard care. It also looks at safety, because inhaled medicine can cause side effects and needs careful monitoring.
This trial tests an inhaled medication called treprostinil palmitil to see if it can slow the decline of lung function in people with progressive pulmonary fibrosis (PPF), a condition where lung scarring worsens over time. It's for people whose lung disease is getting worse despite standard care, and it may help preserve their breathing ability.
This study tests a new oral medication, HSK44459, for people with IPF. It aims to see if the drug is safe and effective compared to a placebo, and might help slow the progression of the disease.
This trial is testing a new medication called HSK50042 to see if it can help people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. If you have IPF and meet some basic health criteria, you might be able to join.
This trial tests a new drug called HRS-9813 for people with pulmonary fibrosis (scarring in the lungs) that continues to worsen. It looks at whether the drug can slow down the disease compared to a placebo.
This trial tests the long-term safety and effectiveness of an oral medication (HSK44459) in people with idiopathic pulmonary fibrosis (IPF), a lung disease that causes scarring. If you were in the earlier study profile, this study lets you keep taking the medication to see if it continues to help over time.
Hear when a new Progressive Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.